Jacob Stern leads operations and investments for the personalized medical team surrounding Sid Sijbrandij. Jacob is pioneering a data-driven, N=1 approach to treating Sid’s high-grade osteosarcoma, overseeing a portfolio of experimental therapeutics and novel diagnostic assays.

Jacob previously led the spatial transcriptomics product line at 10x Genomics. Prior to his work in life sciences, he focused on data integration at Palantir Technologies and strategy at BCG. He holds an MBA and BA from Stanford University.